Bayesian Capital Management, LP Clovis Oncology, Inc. Transaction History

Bayesian Capital Management, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$4.81 - $10.34 $106,300 - $228,514	-22,100 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$4.13 - $6.41 $5,782 - $8,974	1,400 Added 6.76%	22,100 $106,000
Q3 2020 Nov 12, 2020	SELL	$4.82 - $7.72 $25,546 - $40,916	-5,300 Reduced 20.38%	20,700 $121,000
Q2 2020 Aug 14, 2020	SELL	$5.69 - $9.69 $387,164 - $659,336	-68,043 Reduced 72.35%	26,000 $176,000
Q1 2020 May 15, 2020	BUY	$3.77 - $11.0 $354,542 - $1.03 Million	94,043 New	94,043 $598,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.